Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ: AKTS) with a Outperform rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage